Compared with CD4+ Tregs, CD8+ CTLs and other anti-tumor cells have lower adaptability to the TME, are more vulnerable to high ROS and other factors, and become exhausted during tumor development [61]. The gene discussed is CD8A; the disease is neoplasm.